TY  - JOUR
AU  - Hilvo, Mika
AU  - Meikle, Peter J
AU  - Pedersen, Eva Ringdal
AU  - Tell, Grethe S
AU  - Dhar, Indu
AU  - Brenner, Hermann
AU  - Schöttker, Ben
AU  - Lääperi, Mitja
AU  - Kauhanen, Dimple
AU  - Koistinen, Kaisa M
AU  - Jylhä, Antti
AU  - Huynh, Kevin
AU  - Mellett, Natalie A
AU  - Tonkin, Andrew M
AU  - Sullivan, David R
AU  - Simes, John
AU  - Nestel, Paul
AU  - Koenig, Wolfgang
AU  - Rothenbacher, Dietrich
AU  - Nygård, Ottar
AU  - Laaksonen, Reijo
TI  - Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.
JO  - European heart journal
VL  - 41
IS  - 3
SN  - 1522-9645
CY  - Oxford
PB  - Oxford University Press
M1  - DKFZ-2019-01601
SP  - 371-380
PY  - 2020
N1  - 2020 Jan 14;41(3):371-380
AB  - Distinct ceramide lipids have been shown to predict the risk for cardiovascular disease (CVD) events, especially cardiovascular death. As phospholipids have also been linked with CVD risk, we investigated whether the combination of ceramides with phosphatidylcholines (PCs) would be synergistic in the prediction of CVD events in patients with atherosclerotic coronary heart disease in three independent cohort studies.Ceramides and PCs were analysed using liquid chromatography-mass spectrometry (LC-MS) in three studies: WECAC (The Western Norway Coronary Angiography Cohort) (N = 3789), LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) trial (N = 5991), and KAROLA (Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung) (N = 1023). A simple risk score, based on the ceramides and PCs showing the best prognostic features, was developed in the WECAC study and validated in the two other cohorts. This score was highly significant in predicting CVD mortality [multiadjusted hazard ratios (HRs; 95
LB  - PUB:(DE-HGF)16
C6  - pmid:31209498
DO  - DOI:10.1093/eurheartj/ehz387
UR  - https://inrepo02.dkfz.de/record/144050
ER  -